The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Receptor-mediated targeted drug delivery systems for treatment of inflammatory bowel disease: Opportunities and emerging strategies
Open accessAbstract
Inflammatory bowel disease (IBD) is a chronic intestinal disease with painful clinical manifestations and high risks of cancerization. With no curative therapy for IBD at present, the development of effective therapeutics is highly advocated. Drug delivery systems have been extensively studied to transmit therapeutics to inflamed colon sites through the enhanced permeability and retention (EPR) effect caused by the inflammation. However, the drug still could not achieve effective concentration value that merely utilized on EPR effect and display better therapeutic efficacy in the inflamed region because of nontargeted drug release. Substantial researches have shown that some specific receptors and cell adhesion molecules highly expresses on the surface of colonic endothelial and/or immune cells when IBD occurs, ligand-modified drug delivery systems targeting such receptors and cell adhesion molecules can specifically deliver drug into inflamed sites and obtain great curative effects. This review introduces the overexpressed receptors and cell adhesion molecules in inflamed colon sites and retrospects the drug delivery systems functionalized by related ligands. Finally, challenges and future directions in this field are presented to advance the development of the receptor-mediated targeted drug delivery systems for the therapy of IBD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002
Ng, S. C., Shi, H. Y., Hamidi, N., Underwood, F. E., Tang, W., Benchimol, E. I., Panaccione, R., Ghosh, S., Wu, J. C. Y., Chan, F. K. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32448-0 · Cited by 6,087
The gut microbiota shapes intestinal immune responses during health and disease
Round, J. L., & Mazmanian, S. K. (2009) · Nature Reviews Immunology · doi:10.1038/nri2515 · Cited by 5,029
Unravelling the pathogenesis of inflammatory bowel disease
Xavier, R. J., & Podolsky, D. K. (2007) · Nature · doi:10.1038/nature06005 · Cited by 4,364
Getting to the site of inflammation: the leukocyte adhesion cascade updated
Ley, K., Laudanna, C., Cybulsky, M. I., & Nourshargh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2156 · Cited by 4,354
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Understanding and Preventing the Global Increase of Inflammatory Bowel Disease
Kaplan, G. G., & Ng, S. C. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.10.020 · Cited by 1,224
Recent progress in drug delivery
Li, C., Wang, J., Wang, Y., Gao, H., Wei, G., Huang, Y., Yu, H., Gan, Y., Wang, Y., Mei, L., et al. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.08.003 · Cited by 818
Self-citationQuantum dots in imaging, drug delivery and sensor applications
Matea, C., Mocan, T., Tabaran, F., Pop, T., Mosteanu, O., Puia, C., Iancu, C., & Mocan, L. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s138624 · Cited by 666
Hyaluronan, a Crucial Regulator of Inflammation
Petrey, A. C., & de la Motte, C. A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00101 · Cited by 514
Cited by
Multifunctional nanoparticle-mediated combining therapy for human diseases
Li, X., Peng, X., Zoulikha, M., Boafo, G. F., Magar, K. T., Ju, Y., & He, W. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01668-1 · Cited by 521
Role of the Gut Microbiota and Its Metabolites in Tumorigenesis or Development of Colorectal Cancer
Qu, R., Zhang, Y., Ma, Y., Zhou, X., Sun, L., Jiang, C., Zhang, Z., & Fu, W. (2023) · Advanced Science · doi:10.1002/advs.202205563 · Cited by 297
Liu, C., Yan, X., Zhang, Y., Yang, M., Ma, Y., Zhang, Y., Xu, Q., Tu, K., & Zhang, M. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01421-w · Cited by 285
Turmeric-derived nanovesicles as novel nanobiologics for targeted therapy of ulcerative colitis
Gao, C., Zhou, Y., Chen, Z., Li, H., Xiao, Y., Hao, W., Zhu, Y., Vong, C. T., Farag, M. A., Wang, Y., et al. (2022) · Theranostics · doi:10.7150/thno.73650 · Cited by 278
Self-citationZhang, C., Li, J., Xiao, M., Wang, D., Qu, Y., Zou, L., Zheng, C., & Zhang, J. (2022) · Chinese Chemical Letters · doi:10.1016/j.cclet.2022.03.110 · Cited by 156
Metadata
- Authors
- Liu, P., Gao, C., Chen, H., Vong, C. T., Wu, X., Tang, X., Wang, S., & Wang, Y.
- Venue
- Acta Pharmaceutica Sinica B
- Publisher
- Elsevier BV
- Published
- 2021-09
- Volume
- 11
- Issue
- 9
- Pages
- 2798-2818
- ISSN
- 2211-3835 (ISSN-L)
- OpenAlex
- W3095291274
- Cited by
- 160
- References
- 13
- FWCI
- 4.84
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Receptor-mediated targeted drug delivery systems for treatment of inflammatory bowel disease: Opportunities and emerging strategies. https://app.cochat.ai/papers/10.1016/j.apsb.2020.11.003
- The paper
- Liu, P., Gao, C., Chen, H., Vong, C. T., Wu, X., Tang, X., Wang, S., & Wang, Y. (2021). Receptor-mediated targeted drug delivery systems for treatment of inflammatory bowel disease: Opportunities and emerging strategies. Acta Pharmaceutica Sinica B. https://doi.org/10.1016/j.apsb.2020.11.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.